Nanobiotix announces a license agreement with Janssen Pharmaceutica for worldwide co-development and commercialization of potential first-in-class radioenhancer NBTX R3.
Nanobiotix a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTX R3.